Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Pharmaceuticals 2012, 5(5), 514-528; doi:10.3390/ph5050514
Review

Sphingosine 1-Phosphate Receptor 1 as a Useful Target for Treatment of Multiple Sclerosis

*  and
Received: 5 April 2012; in revised form: 24 April 2012 / Accepted: 15 May 2012 / Published: 18 May 2012
(This article belongs to the Special Issue Immunosuppressant Drugs)
View Full-Text   |   Download PDF [725 KB, uploaded 18 May 2012]
Abstract: Sphingosine 1-phosphate (S1P), a lysophospholipid mediator, is generated from sphingosine by sphingosine kinases and binds five known cell surface receptors. S1P receptor 1 (S1P1) plays an essential role in lymphocyte egress from secondary lymphoid organs (SLO), as evinced by the inability of lymphocytes to exit from the SLO in mice lacking lymphocytic S1P1. Fingolimod hydrochloride (FTY720) is a first-in-class, orally active, S1P receptor modulator with a structure closely related to sphingosine. FTY720 was first synthesized by chemical modification of a natural product, myriocin. FTY720 is effectively converted to an active metabolite, FTY720 phosphate (FTY720-P) by sphingosine kinases. FTY720-P shows high affinity to 4 of the S1P receptors (S1P1, S1P3, S1P4, and S1P5). In particular, FTY720-P strongly induces internalization and degradation of S1P1, inhibits S1P responsiveness of lymphocytes in the SLO, and acts as a functional antagonist at lymphocytic S1P1. Consequently, FTY720 inhibits S1P1-dependent lymphocyte egress from the SLO to decrease circulation of lymphocytes including autoreactive Th17 cells and is highly effective in experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS). Because FTY720 shows a superior efficacy in relapsing remitting MS patients compared to intramuscular interferon-β-1a (Avonex®), S1P1 is presumed to be a useful target for the therapy of MS.
Keywords: sphingosine 1-phasphate (S1P); S1P receptor 1 (S1P1); fingolimod (FTY720); lymphocyte egress; immunomodulator; experimental autoimmune encephalomyelitis (EAE); multiple sclerosis (MS); therapy sphingosine 1-phasphate (S1P); S1P receptor 1 (S1P1); fingolimod (FTY720); lymphocyte egress; immunomodulator; experimental autoimmune encephalomyelitis (EAE); multiple sclerosis (MS); therapy
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Chiba, K.; Adachi, K. Sphingosine 1-Phosphate Receptor 1 as a Useful Target for Treatment of Multiple Sclerosis. Pharmaceuticals 2012, 5, 514-528.

AMA Style

Chiba K, Adachi K. Sphingosine 1-Phosphate Receptor 1 as a Useful Target for Treatment of Multiple Sclerosis. Pharmaceuticals. 2012; 5(5):514-528.

Chicago/Turabian Style

Chiba, Kenji; Adachi, Kunitomo. 2012. "Sphingosine 1-Phosphate Receptor 1 as a Useful Target for Treatment of Multiple Sclerosis." Pharmaceuticals 5, no. 5: 514-528.



Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert